Cutting-edge Platform Empress Therapeutics' innovative Empress Chemilogics(TM) platform integrates DNA insights with drug-like chemistry to create advanced oral medicines swiftly, opening opportunities for partnership with companies seeking novel solutions.
Strategic Hiring The recent appointment of Dawn Thompson, a reputable figure in biotechnology, as Senior Vice President at Empress Therapeutics signifies a strategic move to enhance the platform development, presenting possibilities for collaborations with emerging talent in the industry.
Favorable Funding With a funding of $50M and revenue potential in the range of $0 - 10M, Empress Therapeutics is in a financially stable position to explore partnerships with organizations looking to invest in cutting-edge biotechnology ventures.
Competitive Landscape In a market with comparable companies like Inozyme Pharma and TRexBio, Empress Therapeutics stands out with its unique approach, offering a competitive edge to potential clients looking for differentiated biotech solutions.
Strategic Location Strategically based in Watertown, Massachusetts, Empress Therapeutics operates in a vibrant biotechnology hub, offering prime networking opportunities and potential collaborations with key players in the industry.
74
$10M$50M
32$10M
501$100M$1B
54$10M
11Empress Therapeutics uses 8 technology products and services including Docker, Google Hosted Libraries, Google Font API, and more. Explore Empress Therapeutics's tech stack below.
| Empress Therapeutics Email Formats | Percentage |
| FLast@empresstx.com | 48% |
| Last.First@empresstx.com | 2% |
| FLast@empresstx.com | 48% |
| Last.First@empresstx.com | 2% |
Biotechnology ResearchMassachusetts, United States11-50 Employees
Founded by Flagship Pioneering in 2020, Empress Therapeutics generates good medicines, fast, by starting with chemistry inside the human body. The Empress Chemilogics(TM) platform uses novel insights that connect the lines of code in DNA with drug-like chemistry made in the human body to create first- or best-in-class oral medicines for a broad range of diseases quickly, predictably, and cost-effectively.
Company Overview
Funding & FinancialsEmpress Therapeutics has raised a total of $50M of funding over 1 rounds. Their latest funding round was raised on Jun 21, 2023 in the amount of $50M.
Empress Therapeutics's revenue is in the range of $10M
Funding & FinancialsEmpress Therapeutics has raised a total of $50M of funding over 1 rounds. Their latest funding round was raised on Jun 21, 2023 in the amount of $50M.
Empress Therapeutics's revenue is in the range of $10M
1-888-653-2347 
support@leadiq.com